Bolt Biotherapeutics GAAP EPS of -$0.29, revenue of $1.2M

Stock Information for Bolt Biotherapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody(TM) ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.